GeneDx (Old)
GeneDx is a privately-held genetic testing company providing whole exome and whole genome sequencing for rare disease diagnosis, serving 75,000+ clinicians, patients and families, health systems, and biopharma partners. The company leverages its proprietary GeneDx Infinity dataset of 2.5M+ tests and MIMI Ranker AI tool to deliver AI-augmented genomic interpretation.
- Company typePrivate
- Founded2000
- HeadquartersStamford, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What GeneDx (Old) does
GeneDx is a privately-held genetic testing company founded in 2000, operating as GeneDx, LLC with headquarters in Stamford, CT and a laboratory facility in Gaithersburg, MD. The company specializes in rare disease diagnosis through whole exome sequencing (ExomeDx) and whole genome sequencing (GenomeDx), with rapid turnaround variants including the GenomeDx ultraRapid platform for NICU/PICU critical care and GenomeDx Prenatal for fetal anomaly detection. GeneDx serves four primary customer segments: healthcare providers (75,000+ clinicians across pediatric neurology, general pediatrics, genetic counseling, and maternal-fetal medicine), patients and families, health systems (via Epic Aura EHR integration), and biopharma companies seeking data and research partnerships. The company is recognized as the #1 genetic test brand among pediatric and genetic specialists and is named one of Fast Company's Most Innovative Companies of 2025.
The company's competitive position is anchored by GeneDx Infinity, one of the world's largest rare disease genomic datasets containing 2.5+ million genetic tests, nearly 1 million exomes and genomes, 8+ million phenotypic data points, and 1.4+ billion clinical datapoints. AI-driven variant interpretation is enabled through MIMI Ranker, a proprietary tool that ranks 98% of diagnostic variants in the top 3 candidates across 16,000+ validation cases. Revenue is generated primarily through fee-for-service genetic testing billed to commercial insurance, Medicaid (36 states), Medicare, and TRICARE, supplemented by biopharma data partnership revenue. The company is in-network for 79% of commercially insured patients and reported Q3 2025 revenue of $116.7 million with 52% year-over-year growth and $14.7 million in net income.
GeneDx (Old) firmographics
Firmographics- Name
- GeneDx (Old)
- Legal name
- GeneDx, LLC
- Website
- https://genedx.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- GeneDx is a privately-held genetic testing company providing whole exome and whole genome sequencing for rare disease diagnosis, serving 75,000+ clinicians, patients and families, health systems, and biopharma partners. The company leverages its proprietary GeneDx Infinity dataset of 2.5M+ tests and MIMI Ranker AI tool to deliver AI-augmented genomic interpretation.
- Ownership category
- akta.pro rank
GeneDx (Old) industry classification
Industry- Product category
- Clinical Genetic Testing Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
Keywords
Where GeneDx (Old) is headquartered
LocationHeadquarters
- HQ city
- Stamford
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
GeneDx (Old) business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Genetic Testing Services: GeneDx generates revenue primarily through billing for genetic testing services (whole exome, whole genome, trio, targeted panels, prenatal). Tests are billed to commercial insurance, Medicaid, Medicare, and TRICARE. Self-pay options, interest-free payment plans, and financial assistance programs are also available. The company is an in-network provider for 79% of commercially insured patients.
- Biopharma Data and Research Services: GeneDx partners with biopharma companies to leverage GeneDx Infinity™ data for target identification, natural history studies, clinical trial design, patient identification, health economics and outcomes research. Revenue is derived from data partnerships, research collaborations, and potentially licensing of genomic insights.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | One time/ perpetual license | Provider/telehealth intake service fee |
| Freemium | Pay-as-you-go | Genome Medical genetic counseling (self-pay) |
| Subscription | Monthly | Insurance-covered testing |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
GeneDx (Old) product offering
Product offeringCore offering
GeneDx is a clinical genomics company that performs whole exome sequencing (ExomeDx) and whole genome sequencing (GenomeDx), including rapid and ultraRapid tests for NICU/PICU patients, prenatal tests (GenomeDx Prenatal), trio testing, and targeted panels, to diagnose rare and inherited diseases. It also operates GeneDx Infinity, one of the world's largest rare disease genomic datasets (2.5M+ tests, ~1M exomes/genomes, 8M+ phenotypic data points), which it monetizes through biopharma data and research partnerships. AI-powered variant prioritization is delivered via MIMI Ranker.
Product overview
GeneDx is a genetic testing company offering a comprehensive portfolio of genomic diagnostics centered on whole exome sequencing (ExomeDx) and whole genome sequencing (GenomeDx) products. The core testing suite includes standard and rapid turnaround options (GenomeDx ultraRapid) for critically ill patients, prenatal testing (GenomeDx Prenatal), and trio testing that incorporates parental samples for improved diagnostic yield. The company operates GeneDx Infinity, a proprietary data platform containing one of the world's largest rare disease genomic datasets. AI-powered variant interpretation is enabled through MIMI Ranker. GeneDx serves providers, patients and families, health systems, and biopharma partners across pediatric neurology, general pediatrics, genetic counseling, and maternal-fetal medicine specialties.
Differentiator
Problem solved
Functional benefit
Brands
- GeneDx Infinity: One of the most powerful tools for accelerating diagnoses and fueling drug discovery. Draws on 2.5+ million genetic tests, nearly 1 million exomes and genomes, and 8 million phenotypic data points.
- GenomeDx
- ExomeDx
- MIMI Ranker
- DNAvisit
- Genome Medical
Products and services
- ExomeDx (Whole Exome Sequencing) Whole exome sequencing test that analyzes the protein-coding portions of approximately 20,000 genes to identify genetic causes of rare and inherited conditions, offering higher diagnostic yield than chromosomal microarray or targeted gene panels. Sold to healthcare providers and accessed by patients via provider order or telehealth partnership.
- GenomeDx (Whole Genome Sequencing) Whole genome sequencing test providing comprehensive analysis of a patient's entire genome including non-coding regions, enabling the greatest chance of identifying the genetic changes responsible for rare and complex conditions. Ordered by healthcare providers; supported by GeneDx provider portal and at-home sample collection.
- GenomeDx Prenatal Trio-based whole genome sequencing diagnostic test specifically designed for fetal anomalies detected during pregnancy, providing genomic insights with less than two-week turnaround time. Covers prenatal indications including congenital heart disease, skeletal dysplasia, and brain and kidney malformations.
- GenomeDx ultraRapid (proband, duo, trio) Rapid whole genome sequencing for critically ill infants in NICU/PICU settings, delivering results in as soon as 48 hours. Available in proband, duo (patient plus one parent), and trio (patient plus both parents) configurations to accelerate diagnostic certainty.
- Trio Testing Genetic testing approach that analyzes DNA from the patient plus both biological parents to improve diagnostic yield and reduce inconclusive findings, distinguishing de novo from inherited variants and enabling more confident clinical decisions.
- GeneDx Infinity One of the world's largest rare disease genomic datasets combining 2.5M+ genetic tests, nearly 1M exomes and genomes, and 8M+ phenotypic data points. Connected with Komodo Health real-world evidence data to support biopharma in target identification, natural history studies, clinical trial design, patient identification, and health economics and outcomes research.
- Prenatal Genetic Testing Comprehensive prenatal genetic testing services including amniotic fluid collection and analysis for detecting fetal genetic conditions during pregnancy, available to maternal-fetal medicine specialists.
- Targeted Variant Testing Focused genetic testing for specific known variants or targeted gene panels when the genetic cause is suspected to lie within particular genes, available to providers and patients.
Quantifiable outcome
- Diagnostic yield 17% greater than standard testing
- +7 more outcomes
Companies that use GeneDx (Old)
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles4 records
GeneDx (Old) technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability5 records
Feature4 records
GeneDx (Old) partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- IlluminacoreIllumina partnered with GeneDx to pilot its Constellation Mapped Read Technology, designed to uncover challenging genomic insights. The pilot study evaluated the technology's performance on challenging genomic regions using 160 samples. The technology is scheduled for release in the first half of 2026 and aims to enhance DNA sequencing applications in research and clinical markets.
- Komodo HealthcoreGeneDx partners with Komodo Health to connect genomic and phenotypic data from GeneDx Infinity™ with longitudinal real-world claims data, creating one of the most comprehensive rare disease datasets in healthcare. This partnership supports biopharma in target identification, natural history studies, clinical trial design, patient identification, and health economics and outcomes research.
- Genome MedicalcoreGenome Medical provides telehealth genetic counseling and test ordering services for GeneDx, enabling patients to virtually meet with board-certified genetic counselors and start the testing process from the comfort of their home. Genome Medical's clinical team includes experienced genetic counselors, medical geneticists, and specialists who provide care across all 50 states.
- DNAvisitminorDNAvisit is a network of medical providers partnered with GeneDx to support patients seeking genetic testing for developmental delays. DNAvisit providers review patient intake, select appropriate tests, place orders, and discuss results with families through virtual visits.
- Epic (Epic Aura)coreGeneDx offers Epic Aura EHR integration for health systems, enabling seamless ordering and result delivery within the Epic electronic health record system to support precision medicine across hospital networks.
Scale indicators10 records
Recent moves6 records
Expansion highlights8 records
GeneDx (Old) competitors and assessment
Company assessmentMarket position
Competitive moat7 records
Key highlights7 records
Customer concentration
GeneDx (Old) social profiles
Digital presenceGeneDx (Old) compliance and trust
Trust signalCompliance1 record
GeneDx (Old) financial estimates
Financial estimateRevenue estimate
Valuation estimate
GeneDx (Old) leadership team
Management profileNumber of profiles
Profiles3 records
GeneDx (Old) funding detail
Funding detailFunding overview
Funding rounds7 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GeneDx (Old) M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GeneDx (Old)
What does GeneDx (Old) do?
GeneDx is a clinical genomics company that performs whole exome sequencing (ExomeDx) and whole genome sequencing (GenomeDx), including rapid and ultraRapid tests for NICU/PICU patients, prenatal tests (GenomeDx Prenatal), trio testing, and targeted panels, to diagnose rare and inherited diseases. It also operates GeneDx Infinity, one of the world's largest rare disease genomic datasets (2.5M+ tests, ~1M exomes/genomes, 8M+ phenotypic data points), which it monetizes through biopharma data and research partnerships. AI-powered variant prioritization is delivered via MIMI Ranker.
Is GeneDx (Old) a public or private company?
GeneDx (Old) is a private company. It is classified as unknown and is currently operating.
When was GeneDx (Old) founded?
GeneDx (Old) was founded in 2000. It employs 1,001 to 5,000 people.
Where is GeneDx (Old) based?
GeneDx (Old) is headquartered in Stamford, United States, in the North America region.
How does GeneDx (Old) make money?
Two revenue lines are on record. Genetic Testing Services are the primary driver. The others are biopharma Data and Research Services.
Does GeneDx (Old) have an API?
No public API is recorded for GeneDx (Old).
What industry is GeneDx (Old) in?
GeneDx (Old)'s product category is Clinical Genetic Testing Services. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 621511 and its SIC code is 8071.